NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

Not Yet RecruitingPhase 2

Sponsor: NewAmsterdam Pharma

Conditions: Preclinical Alzheimer's Disease

Interventions: Obicetrapib 10 mg, Matching placebo tablets

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Eligibility overview

Sex: ALL

Age: 55 Years to 85 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* participants with preclinical AD

Exclusion Criteria:

* APOE genotype not meeting protocol-defined eligibility criteria